1
EXHIBIT 10.3
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
BETWEEN CYTRX CORPORATION AND ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
2
AMENDED AND RESTATED
EMPLOYMENT AGREEMENT
BETWEEN
CYTRX CORPORATION
AND
▇▇▇▇ ▇. ▇▇▇▇▇▇▇
This Amended and Restated Employment Agreement ("Agreement") is made
and executed this 1st day of September, 1999 (the "Effective Date"), by and
between CYTRX CORPORATION ("CytRx" or the "Company"), a Delaware Corporation
having its principal place of business at ▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇/▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇, and ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ("▇▇. ▇▇▇▇▇▇▇") who
currently resides at ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇.
WHEREAS, CytRx originally employed ▇▇. ▇▇▇▇▇▇▇ as its President and
Chief Executive Officer pursuant to an Employment Agreement dated March 13,
1989. After several amendments, the original Employment Agreement was amended
and restated effective as of January 1, 1995. That amended and restated
agreement was subsequently amended by Amendment No. 1 dated April 16, 1997,
Amendment No. 2 dated August 28, 1997, and Amendment No. 3 dated April 8, 1998
(collectively, the "1995 Agreement").
WHEREAS, the Compensation Committee of the Board of Directors of the
Company at its meeting on September 1, 1999, approved certain changes to the
terms of the employment of ▇▇. ▇▇▇▇▇▇▇ with the Company.
WHEREAS, as a result of the foregoing, both the Company and ▇▇. ▇▇▇▇▇▇▇
concluded that the 1995 Agreement should be amended and restated so as to
incorporate all prior amendments and reflect the most recent amendments.
WHEREAS, this Agreement amends and restates the 1995 Employment
Agreement.
WHEREAS, the Board has authorized the execution of this Agreement.
NOW, THEREFORE, in consideration of the mutual covenants and promises
made in this Agreement, the parties do hereby agree as follows:
1. EMPLOYMENT. CytRx agrees to and does hereby engage and employ ▇▇.
▇▇▇▇▇▇▇ as President and Chief Executive Officer of CytRx Corporation for the
term and upon the
1
3
terms and conditions set forth herein, and ▇▇. ▇▇▇▇▇▇▇ accepts such offer of
employment. It is also understood and agreed that ▇▇. ▇▇▇▇▇▇▇ will serve as a
director of the Company, without additional compensation, for any term he is
elected to serve. During the term of this Agreement, the Board of Directors will
take such actions as may be required to nominate and recommend ▇▇. ▇▇▇▇▇▇▇ for
election as a director by the shareholders. ▇▇. ▇▇▇▇▇▇▇ agrees to discharge his
duties hereunder in accordance with the direction of the Board of Directors of
CytRx and to follow diligently and implement faithfully all management policies
and decisions communicated to him by the Board of Directors. During the
employment of ▇▇. ▇▇▇▇▇▇▇ by CytRx, ▇▇. ▇▇▇▇▇▇▇ shall devote his full and
undivided time, attention, energies and loyalty to the Company's business but
the foregoing shall not be construed to prevent ▇▇. ▇▇▇▇▇▇▇ from making
investments in other businesses or enterprises or engaging in any other business
activity that does not interfere with ▇▇. ▇▇▇▇▇▇▇'▇ duties under this Agreement,
or conflict with his obligations under Paragraph 10 hereof or otherwise
represent a conflict of interest with his duties to CytRx. Notwithstanding the
above, ▇▇. ▇▇▇▇▇▇▇ may serve on the Board of Directors of companies not
affiliated with CytRx, and receive compensation in connection therewith, if such
position is approved by the Board of Directors of CytRx.
2. TERM AND RENEWAL. The term of ▇▇. ▇▇▇▇▇▇▇'▇ employment hereunder will
be for a period commencing on the Effective Date and continuing until December
31, 2002 (the "Expiration Date"), unless ▇▇. ▇▇▇▇▇▇▇'▇ employment is terminated
by either party pursuant to Paragraph 7 of this Agreement.
3. SALARY.
(a) For services provided hereunder, ▇▇. ▇▇▇▇▇▇▇ will be paid an
annual base salary. ▇▇. ▇▇▇▇▇▇▇'▇ base salary as of the Effective Date is Three
Hundred Fifty Thousand Dollars ($350,000). The base salary shall be reviewed by
the Board of Directors of the Company no less than once each 18 months. The base
salary will be increased from time to time consistent with the average overall
merit increases, if any, granted to all employees as a whole for such year, but
will not be decreased. If the base salary is increased, then the increased
amount shall be deemed the "base salary" for all purposes under this Agreement.
(b) It is understood and contemplated that, in addition to the
foregoing annual base salary, ▇▇. ▇▇▇▇▇▇▇ will be eligible to receive cash
bonuses in each calendar year during the term of this Agreement in such amounts,
if any, as shall be determined from time to time by the Board of Directors of
the Company in its sole discretion. The bonus for each year shall accrue, and
become due and payable, on January 1 of the following year, or any later time
requested by ▇▇. ▇▇▇▇▇▇▇. If this Agreement expires on the Expiration Date, then
the obligation of the Company to pay a bonus to ▇▇. ▇▇▇▇▇▇▇ on January 1, 2003,
shall survive such expiration, and the Company shall pay such bonus to ▇▇.
▇▇▇▇▇▇▇ as if this Agreement remained in full force and effect.
2
4
4. FRINGE BENEFITS. ▇▇. ▇▇▇▇▇▇▇, during the period of his employment
hereunder, will receive fringe benefits such as insurance, vacation leave, sick
leave and participation in any retirement plan as may exist from time to time
for all other executive officers of the Company; provided, however, that, during
the term of this Agreement, the Company shall maintain at its expense a
long-term disability policy for the benefit of ▇▇. ▇▇▇▇▇▇▇, which will provide
coverage equal to a percentage of ▇▇. ▇▇▇▇▇▇▇'▇ base salary consistent with the
percentage coverage provided to the other executive officers of the Company.
Such insurance shall include any group long-term disability insurance on ▇▇.
▇▇▇▇▇▇▇ that the Company maintains for the benefit of its senior executives. ▇▇.
▇▇▇▇▇▇▇ will not receive an automobile or automobile expense allowance. ▇▇.
▇▇▇▇▇▇▇ shall be entitled to six weeks of vacation leave, annually, which shall
be paid at his base salary, and shall accrue and be used in accordance with the
policies and procedures of the Company.
5. REIMBURSEMENT OF BUSINESS EXPENSES. The Company will promptly reimburse
▇▇. ▇▇▇▇▇▇▇ for all business expenses incurred by him in connection with the
business of the Company in accordance with regular Company policy regarding the
nature and amount of expenses and the maintenance and submission of receipts and
records necessary for the Company to document them as proper business expenses.
6. THE EXECUTIVE WARRANTS.
(a) Current Status. Exhibit A hereto contains a list of all of the
warrants to acquire CytRx common stock ("Executive Warrants") held by ▇▇.
▇▇▇▇▇▇▇ as of September 1, 1999, including with respect to each such warrant:
the grant date, the expiration date, the number of shares, the exercise price
and the vesting status or schedule.
(b) Other Registration, Vesting and Exercise Rights.
(1) In addition to any other registration rights ▇▇.
▇▇▇▇▇▇▇ may have, the Company has filed or shall file with the Securities and
Exchange Commission a registration statement to register the shares of CytRx
common stock to be acquired under Executive Warrants under the Securities Act of
1933, and shall use its best efforts to keep such registration statement
effective and current for as long as ▇▇. ▇▇▇▇▇▇▇ has the right to exercise the
Executive Warrants and for a period of six (6) months thereafter, if such
additional period is required to allow ▇▇. ▇▇▇▇▇▇▇ to dispose of the acquired
shares in an orderly fashion.
(2) All rights to purchase CytRx stock pursuant to the
Executive Warrants that have vested prior to or upon the termination of ▇▇.
▇▇▇▇▇▇▇'▇ employment with the Company may be exercised by ▇▇. ▇▇▇▇▇▇▇ at any
time until the expiration of such rights under the applicable warrant agreement,
even after ▇▇. ▇▇▇▇▇▇▇'▇ employment with the Company has been terminated. All
rights to purchase CytRx stock pursuant to the Executive Warrants that by their
terms vest after the termination of ▇▇. ▇▇▇▇▇▇▇'▇
3
5
employment with the Company shall terminate on the effective date of the
termination of ▇▇. ▇▇▇▇▇▇▇'▇ employment.
(3) For all purposes of this Agreement and the Executive
Warrants, (A) in the event of the death of ▇▇. ▇▇▇▇▇▇▇, the Executive Warrants
may be exercised by his personal representative, executor, or heirs (whether by
will or by the laws of descent and distribution), and (B) in the event of the
incapacity of ▇▇. ▇▇▇▇▇▇▇, the Executive Warrants may be exercised by his duly
appointed attorney-in-fact or other authorized person, in each case, to the same
extent such warrants have vested and are exercisable by the Holder (as defined
in the Executive Warrants) in accordance with the terms thereof.
7. TERMINATION OF EMPLOYMENT AND THIS AGREEMENT.
(a) If ▇▇. ▇▇▇▇▇▇▇'▇ employment is terminated by the Company for
cause (as hereinafter defined) or if ▇▇. ▇▇▇▇▇▇▇ voluntarily leaves the
employment of the Company prior to the Expiration Date, the Company will pay ▇▇.
▇▇▇▇▇▇▇ the equivalent of three (3) months' salary at the base salary, and three
(3) months continuation of fringe benefits then being received by ▇▇. ▇▇▇▇▇▇▇.
For purposes of this Agreement, termination "for cause" means termination of ▇▇.
▇▇▇▇▇▇▇'▇ employment by action of a majority of the members of the Board of
Directors who are not employees of CytRx or any subsidiary, because of:
(1) material breach of contract,
(2) failure or inability to carry out reasonable
directives of the Board of Directors,
(3) conviction of ▇▇. ▇▇▇▇▇▇▇ for a felony, even if such
conviction is subject to appeal,
(4) uncontroverted evidence of falsification of records
or statements of the Company,
(5) uncontroverted evidence of intentional misuse of
Company funds or property, or
(6) other substantial misconduct which, in the reasonable
judgment of the Board, results in material adverse effect, discredit or
disrepute to the Company.
A termination of employment for any cause listed in clauses (1), (2) or
(6) above shall be effective only if ▇▇. ▇▇▇▇▇▇▇ has first been given notice by
the Board of Directors of the alleged breach, failure to perform or misconduct
and such breach, failure to perform or misconduct continues for fifteen days
following the date of such notice.
4
6
(b) If this Agreement expires on the Expiration Date, or if the
sooner termination of ▇▇. ▇▇▇▇▇▇▇'▇ employment and this Agreement is not for
cause, not because of ▇▇. ▇▇▇▇▇▇▇'▇ death or disability and not because of his
voluntary termination of employment, then the Company will continue to make
semi-monthly base salary payments for a period of one year after the Expiration
Date or the earlier effective date of termination; provided, however, that (1)
in the case of the expiration of this Agreement on the Expiration Date, the
one-year salary continuation period shall be reduced by the period of time
before the Expiration Date that the Board of Directors gives ▇▇. ▇▇▇▇▇▇▇ written
notice that it intends to allow the Agreement to expire, or not to pay the full
salary continuation obligation if negotiations to renew the Agreement are
unsuccessful, and (2) in all cases, ▇▇. ▇▇▇▇▇▇▇'▇ rights to receive salary
continuation payments are contingent upon his using his best efforts to find a
new job commensurate with his position as the chief executive officer and member
of the Board of Directors of the Company. If ▇▇. ▇▇▇▇▇▇▇ obtains a position
during the one-year salary continuation period (whether commensurate with his
position with the Company or not) the obligation for salary continuation
hereunder shall be limited to an amount equivalent to the difference, if any,
between the base salary under this Agreement and the base salary paid to him by
his new employer. Fringe benefits provided during employment shall be continued
until ▇▇. ▇▇▇▇▇▇▇ finds another job as provided for under this Subparagraph or
until the end of the one-year salary continuation period, whichever first
occurs.
(c) If ▇▇. ▇▇▇▇▇▇▇'▇ employment and thereby this Agreement is
terminated because of ▇▇. ▇▇▇▇▇▇▇'▇ death, CytRx shall pay any compensation then
due him under this Agreement as of the date of his death to his surviving
spouse, or if there is no surviving spouse, to his estate, and shall make to
such spouse or his estate, as above, semi-monthly payments of salary based on
the annual rate which then would have been applicable to ▇▇. ▇▇▇▇▇▇▇'▇
employment for six (6) months after his death, and provide six (6) months'
continuation of fringe benefits available to his dependents covered for such
benefits at the time of ▇▇. ▇▇▇▇▇▇▇'▇ death. If ▇▇. ▇▇▇▇▇▇▇ becomes permanently
disabled or subject to long term disability during the period of his employment
hereunder, and CytRx terminates this Agreement other than pursuant to Paragraph
7(a), ▇▇. ▇▇▇▇▇▇▇'▇ employment shall be deemed to have been terminated without
cause pursuant to Paragraph 7(b); provided, however, that (1) ▇▇. ▇▇▇▇▇▇▇ shall
not be required to find a new job, and (2) instead of the one-year salary
continuation, an amount equal to his base salary for one year shall be paid to
▇▇. ▇▇▇▇▇▇▇ in variable monthly installments until such amount is exhausted,
with each installment being equal to the amount that when combined with payments
received during such month by ▇▇. ▇▇▇▇▇▇▇ from the Company under its short-term
disability policy, or from one or more insurance companies under long term
disability insurance policies maintained by the Company pursuant to Paragraph 4,
equals the amount of base salary (calculated on a pre-tax basis) that ▇▇.
▇▇▇▇▇▇▇ would have received during such month if this Agreement had not been
terminated. For example, if (1) CytRx terminates this Agreement because ▇▇.
▇▇▇▇▇▇▇ becomes permanently disabled at a time when his annual base salary is
$350,000, (2) ▇▇. ▇▇▇▇▇▇▇
5
7
is eligible immediately to receive monthly short term disability payments from
the Company equal to $29,167 (100% of his base salary) and (3) ▇▇. ▇▇▇▇▇▇▇ will
be eligible after one month to receive long term disability payments from the
insurance carrier equal to $17,500 (60% of his base salary), then CytRx will not
be obligated to make any payment to ▇▇. ▇▇▇▇▇▇▇ for the first month and will be
obligated to pay ▇▇. ▇▇▇▇▇▇▇ $11,667 per month (40% of his base salary) for the
next 2.5 years (30 months). If, in the above example, ▇▇. ▇▇▇▇▇▇▇ ceased for any
reason to qualify for the insurance company payments after the first 11 months,
then the Company shall be obligated to make monthly payments of $29,167 (100% of
his base salary) for the following 8 months ($350,000 less the $116,668 already
paid divided by $29,167), subject to the salary adjustment described in
Paragraph 7(b) if ▇▇. ▇▇▇▇▇▇▇ obtains a position during the 8 month period.
It is understood that permanently disabled and subject to long term
disability shall mean such sickness, as well as physical or mental disability,
that qualifies or, with the passage of time (not to exceed 90 calendar days),
will qualify ▇▇. ▇▇▇▇▇▇▇ to receive benefit payments under at least one of the
long-term disability policies maintained by the Company for ▇▇. ▇▇▇▇▇▇▇ in
accordance with Paragraph 4. In the event of a dispute as to ▇▇. ▇▇▇▇▇▇▇'▇
ability to perform his duties, the Company may refer ▇▇. ▇▇▇▇▇▇▇ to a licensed
practicing physician of CytRx's choice and reasonably satisfactory to ▇▇.
▇▇▇▇▇▇▇, and ▇▇. ▇▇▇▇▇▇▇ agrees to submit to such tests and examinations as such
physician shall deem appropriate. The determination by the physician as to
whether or not ▇▇. ▇▇▇▇▇▇▇ is unable to perform substantially his normal duties
shall conclusively determine such facts for the purposes of this Paragraph 7(c).
Short term illness or injury not amounting to long term disability shall be
treated in accordance with any benefit provided under Paragraph 4 of this
Agreement.
It is also understood that, if CytRx becomes obligated to make payments
to ▇▇. ▇▇▇▇▇▇▇ pursuant to this Paragraph 7(c) because of ▇▇. ▇▇▇▇▇▇▇'▇
disability and, within a reasonable period of time after ▇▇. ▇▇▇▇▇▇▇'▇
termination, a majority of the members of the Board of Directors of the Company
who are not employees of CytRx or any subsidiary determine in good faith that
▇▇. ▇▇▇▇▇▇▇ should have been terminated for cause in accordance with Paragraph
7(a), then the obligations of the Company under this Paragraph 7(c) shall cease
after the Company has paid to ▇▇. ▇▇▇▇▇▇▇ an amount equal to the amount due him
pursuant to Paragraph 7(a) and continued ▇▇. ▇▇▇▇▇▇▇'▇ fringe benefits for the
period of time required by Paragraph 7(a); provided, however, that in no event
shall ▇▇. ▇▇▇▇▇▇▇ be required to repay the Company any amounts paid to him under
this Paragraph 7(c).
8. NO RESTRICTIONS ON ▇▇. ▇▇▇▇▇▇▇'▇ EMPLOYMENT BY CYTRX. ▇▇. ▇▇▇▇▇▇▇
represents as a condition of this Agreement that he is not under any existing
employment agreement, noncompetition agreement or other legally binding
agreement which would prohibit or in any manner restrict his employment
hereunder with CytRx.
6
8
9. EMPLOYEE CONFIDENTIALITY AND INVENTION ASSIGNMENT AGREEMENT. ▇▇.
▇▇▇▇▇▇▇ and the Company are parties to a confidentiality and invention
assignment letter agreement dated November 3, 1994, which shall be deemed to be
incorporated into this Agreement as if fully set forth in this Paragraph 9.
10. RESTRICTIONS ON COMPETITION.
(a) During Employment. In order to protect CytRx's investment,
which includes but is not limited to, time, money and proprietary information,
and in recognition of the unique character of the Trade Secrets and other
Confidential Information which are the basis of CytRx's business and future
business opportunities, in recognition of the worldwide geographic scope of
CytRx's business and/or potential business opportunities and ▇▇. ▇▇▇▇▇▇▇'▇
contemplated role, responsibilities and knowledge therefor, for the entire
period of ▇▇. ▇▇▇▇▇▇▇'▇ employment by CytRx, ▇▇. ▇▇▇▇▇▇▇ agrees that he will not
work as a consultant for or directly or indirectly perform services anywhere in
the world for himself or any other person, firm or corporation in competition
with CytRx. A business in competition with CytRx includes any business activity
being actively investigated or contemplated by CytRx during the period of ▇▇.
▇▇▇▇▇▇▇'▇ employment by CytRx. Without limitation on the foregoing, but by way
of example, businesses currently contemplated by CytRx as being in competition
with it include pharmaceutical businesses engaged in or considering engaging in
manufacture, marketing or development of commercial products in any and all of
the following areas:
(1) Immune system stimulating compounds and methods;
(2) Growth stimulation of animals;
(3) all formulations and methods using the surface-active
copolymers described in U.S. Patent No. 4,801,452,
U.S. Patent Application Serial No. 291,925, U.S.
Patent Application Serial No. 107,358, U.S. Patent
Application Serial No. 208,335, and U.S. Patent
Application Serial No. 150,731.
(4) Mycobacterial and antiviral chemotherapy; and
(5) Vaccine adjuvants.
(b) For two (2) years after termination of employment. In order to
protect CytRx's investment, which includes but is not limited to, time, money
and proprietary information and in recognition of the unique character of the
Trade Secrets and other Confidential Information which are the basis of CytRx's
business and future business opportunities, in recognition of the worldwide
geographic scope of CytRx's business and/or potential business opportunities and
▇▇. ▇▇▇▇▇▇▇'▇ contemplated role, responsibilities and knowledge therefor, for a
period of two (2) years following the
7
9
termination of ▇▇. ▇▇▇▇▇▇▇'▇ employment with CytRx, regardless of the reason
therefor, ▇▇. ▇▇▇▇▇▇▇ agrees that he will not work as a consultant for or
directly or indirectly perform services anywhere in the world for himself or any
other person, firm or corporation in any capacity involving the study,
development, use, manufacture or marketing of all formulations and methods using
the surface-active copolymers described in U.S. Patent No. 4,801,452, U.S.
Patent Application Serial No. 291,925, U.S. Patent Application Serial No.
107,358, U.S. Patent Application Serial No. 208,335, and U.S. Patent Application
Serial No. 150,731.
The foregoing shall not preclude (1) the employment of ▇▇. ▇▇▇▇▇▇▇,
whether as a director, officer, employee, consultant or otherwise, by a research
partner, joint venture partner, licensee or other person, or corporation or
entity that at such time is authorized by CytRx to have rights in or to
restricted products, or (2) the ownership by ▇▇. ▇▇▇▇▇▇▇ of investment
securities representing not more than three (3) per cent of the outstanding
voting securities of company engaged in a pharmaceutical business, whose stock
and/or securities are traded on a national stock exchange or national quotations
system, provided that such investment is passive and not with the intention of
controlling such business.
(c) ▇▇. ▇▇▇▇▇▇▇ will notify the Company at least three (3) weeks
before he is to begin any employment or activity which is described in
Subparagraph (b) of this Paragraph if such employment or activity would commence
within two (2) years after the termination of his employment with CytRx. Such
notice shall be in writing and shall contain a complete description of such
offer, including the position and the responsibilities involved.
(d) ▇▇. ▇▇▇▇▇▇▇ agrees and acknowledges that the restrictions on
competition contained herein including their geographic and product scope are
necessary and reasonable to protect the interests of CytRx and that the
Company's Trade Secrets and other Confidential Information of which he will
become acquainted, if used anywhere in the world during the period in which he
has agreed not to use them or to disclose them would cause CytRx serious and
irreparable damage and harm. ▇▇. ▇▇▇▇▇▇▇ represents and admits that upon the
termination of his employment with CytRx, his experience and capabilities are
such that he can obtain employment engaged in other lines of endeavor and that
the enforcement of this Agreement would not prevent him from earning a
livelihood.
11. ACKNOWLEDGMENTS.
(a) It is understood and contemplated by the parties that if the
obligations undertaken herein in Paragraphs 9 and 10 were breached in any way,
irreparable harm to the Company should be presumed. Damages might be difficult
if not impossible to ascertain, and the faithful observance of the terms of this
Agreement during and after termination of ▇▇. ▇▇▇▇▇▇▇'▇ employment is an
essential condition to his employment with the Company. In light of these
considerations, ▇▇. ▇▇▇▇▇▇▇ agrees that a court of
8
10
competent jurisdiction may immediately enjoin any breach or threatened breach of
Paragraphs 9 and 10 to this Agreement, without waiver of any other rights and
remedies which the Company may have at law.
(b) The obligations undertaken in Paragraphs 9 and 10 of this
Agreement survive the termination of ▇▇. ▇▇▇▇▇▇▇'▇ employment hereunder for the
period specified in each such Paragraph and the termination of this Agreement,
regardless of the reason therefor.
The obligations of CytRx to ▇▇. ▇▇▇▇▇▇▇ following his termination of
employment as set forth in Paragraphs 3(b), 6, and 7 shall survive the
termination of this Agreement until satisfied in accordance with the terms
thereof.
(c) The rights of ▇▇. ▇▇▇▇▇▇▇ under this Agreement are in addition
to any other rights or remedies he may have in law or in equity in the event
CytRx breaches this Agreement, all of which rights and remedies are preserved in
full. Without limiting the foregoing, the rights of ▇▇. ▇▇▇▇▇▇▇ under Paragraph
7 herein do not limit any right he would have upon termination of employment
caused by a breach of CytRx. However, any damages he may sustain shall be
reduced by the payments required to be made under this Agreement.
12. CONSTRUCTION OF AGREEMENT.
(a) It is the intention of the parties to this Agreement that any
construction of this Agreement or Paragraph thereof shall be in favor of its
legality and enforceability and that any construction causing illegality or
unenforceability should yield to a construction favoring legality and
enforceability. Further, the parties agree that should any portion of this
Agreement be judicially held invalid, unenforceable or void, such holding shall
not have the effect of invalidating or voiding any remaining portion of this
Agreement not so declared and that any portion held to be invalid, unenforceable
or void shall, if possible, be deemed amended or reduced in scope, otherwise to
be stricken from this Agreement, but only to the extent required for purposes of
maintaining the legality, validity and enforceability of this Agreement and all
portions thereof in the jurisdiction so holding.
(b) It is understood that use of the word "and" herein included
the disjunctive as well as its injunctive meaning whenever such meaning would
broaden the protection to the Company in the context in which it is used.
13. NO WAIVER. No waiver of any breach of this Agreement may be construed
or deemed as a waiver of any succeeding breach of this Agreement.
14. PERSONAL SERVICES. It is understood and contemplated that this
Agreement provides for personal services of ▇▇. ▇▇▇▇▇▇▇ to the Company.
9
11
15. NO INTERFERENCE. For two (2) years following the termination of ▇▇.
▇▇▇▇▇▇▇'▇ employment hereunder, regardless of the reason therefor, ▇▇. ▇▇▇▇▇▇▇
will not intentionally disrupt or attempt to disrupt the Company's business
relationship with its customers or suppliers, nor solicit any of the Company's
employees to terminate their employment with CytRx.
16. CERTIFICATION BY EMPLOYEE. ▇▇. ▇▇▇▇▇▇▇ certifies that he has received a
copy of this Agreement for review and study before being asked to execute it,
that he has read this Agreement carefully, that he has had a sufficient
opportunity before executing this Agreement to ask questions about it and to
receive answers to any such questions and that he understands the obligations
and rights provided hereunder.
17. ENTIRE AGREEMENT. This Agreement hereto supersedes any and all other
agreements, both oral and in writing, between the parties hereto with respect to
the employment and terms and conditions thereof of ▇▇. ▇▇▇▇▇▇▇ by CytRx, and it
contains all of the parties' representations, covenants and agreements with
respect to such matters. The terms of this Agreement may not be changed orally
but only by a subsequent writing signed by the party against whom enforcement of
such modification is sought.
18. CAPTIONS. Paragraph captions used herein are for convenience of
reference only and shall not change the meaning of the terms of this Agreement.
19. SUCCESSORS AND ASSIGNS. The terms of this Agreement shall inure to the
benefit of any successors and assigns of the Company.
20. GOVERNING LAW. This Agreement shall be construed and governed in
accordance with the laws of the State of Georgia.
21. CORPORATE AUTHORITY. The Company represents and warrants that this
Agreement including the issuance of the warrants (1) has been duly authorized,
executed and delivered by the Company, (2) constitutes a legal, valid and
binding obligation of the Company enforceable in accordance with its terms, and
(3) does not conflict with or result in a violation of the Company's Certificate
of Incorporation, By-laws, or any contract, agreement or instrument to which the
Company is a party or is otherwise bound.
(signatures on following page)
10
12
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
under seal on the date hereof, to be effective as of the Effective Date.
▇▇▇▇ ▇. ▇▇▇▇▇▇▇:
----------------------------
Attest: CYTRX CORPORATION:
------------------- ----------------------------
Corporate Secretary By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(CORPORATE SEAL) Title: Vice President, Human Resources
----------------------------
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
Chairman, CytRx Compensation Committee
13
EXHIBIT A
Executive Warrants
▇▇. ▇▇▇▇▇▇▇ has the following Executive Warrants as of September 1,
1999(1):
WARRANT GRANT EXPIRATION WARRANT EXERCISE VESTING
ID NO. DATE DATE SHARES PRICE STATUS
WI/II-1 2/20/95(2) 12/31/04 500,000 $ 1.00 100%
WI/II-2 2/20/95(3) 02/22/01 50,000 $ 1.00 100%
WIII-2 2/20/95(4) 03/24/03 32,427 $ 1.00 100%
WIV-2 2/20/95(5) 12/31/04 100,000 $ 1.00 100%
None 3/26/96(6) 03/25/06 200,000 $ 1.00 See schedule
(A) below
None 6/6/97(7) 06/05/07 50,000 $ 1.00 See schedule
(B) below
None 4/8/98(8) 04/07/08 450,000 $ 1.00 100%
None 9/1/99 08/31/09 500,000 $2.125 See schedule
(C) below
-----------------------
(1) The Warrant numbers and prices have been adjusted to reflect the reverse
stock split occurring on February 5, 1996.
(2) First amended by Amendment No. 1 on April 16, 1997, to provide that it is
fully vested. Last amended by Amendment No. 2 on September 15, 1998, to reduce
the exercise price from $4.50 to $1.00.
(3) First amended by Amendment No. 1 on April 16, 1997, to provide that it is
fully vested. Last amended by Amendment No. 2 on September 15, 1998, to reduce
the exercise price from $4.50 to $1.00.
(4) First amended by Amendment No. 1 on April 16, 1997, to provide that it is
fully vested. Last amended by Amendment No. 2 on September 15, 1998, to reduce
the exercise price from $7.00 to $1.00.
(5) First amended by Amendment No. 1 on April 16, 1997, to amend vesting
schedule. Now fully vested. Last amended by Amendment No. 2 on September 15,
1998, to reduce the exercise price from $7.00 to $1.00.
(6) First amended by Amendment No. 1 on April 16, 1997 to provide for full
vesting upon a Change in Control, as defined. Later amended by Amendment No. 2
on April 8, 1998 to change the vesting schedule by changing the price target
from $15 to $7.50. Last amended by Amendment No. 2 on September 15, 1998, to
reduce the exercise price from $4.50 to $1.00.
(7) First amended by Amendment No. 1 on April 8, 1998, to change the vesting
schedule by changing the price target from $20 to $12. Last amended by Amendment
No. 2 on September 15, 1998, to reduce the exercise price from $4.125 to $1.00.
(8) Amended by Amendment No. 1 on September 15, 1998, to reduce the exercise
price from $2.9375 to $1.00, and to reduce the vesting target stock prices from
$5 to $1.50, $7.50 to $2.00, and $10 to $2.50, respectively.
14
SCHEDULE (A) - VESTING SCHEDULE FOR 1996 WARRANTS
25,000 on sale/IPO of Vaxcel by December 31, 1998 EXPIRED
25,000 on sale/IPO of VetLife by December 31, 1998 VESTED
25,000 on sale/IPO of Proceutics by December 31, 1998 VESTED
25,000 on third-party funding of RheothRx by December 31, 1998 EXPIRED
50,000 on significant business transaction by December 31, 1998 EXPIRED
50,000 on market price sustaining $7.50 by December 31, 1998 EXPIRED
OR 100% on a Change in Control, as defined.
SCHEDULE (B) - VESTING SCHEDULE FOR 1997 WARRANTS
6,250 on each of March 31, 1999; June 30, 1999; September 30, 1999 and
December 31, 1999 or earlier on death, disability or termination of
employment without cause before 12/31/99 or upon a Change in Control.
25,000 if on or before December 31, 1999 the stock price averages $12
for 10 days or there is a Change in Control.
SCHEDULE (C) - VESTING SCHEDULE FOR 1999 WARRANTS
25,000 on each of March 31, 2000, June 30, 2000, September 30, 2000;
December 31, 2000, March 31, 2001, June 30, 2001, September 30, 2001; December
31, 2001, March 31, 2002, June 30, 2002, September 30, 2002; and December 31,
2002, or as to all 300,000 shares upon a Change of Control on or before December
31, 2002.
50,000 if the stock price reaches $5.00 on or before July 1, 2000 or
upon a Change of Control on or before July 1, 2000.
75,000 on (i) the successful completion of a significant merger,
acquisition or strategic alliance on or before December 31, 2002, (ii)
successfully raising a total of $15,000,000 on or before December 31, 2000, or
(iii) a Change of Control on or before December 31, 2002.
75,000 on (i) the successful NDA/PLA regulatory (FDA) approval of
FLOCOR on or before December 31, 2002, or (ii) a Change of Control on or before
December 31, 2002.
-2-